Original Article
Diagnosis of Childhood Tuberculosis and Host RNA Expression in Africa
N Engl J Med 2014; 370:1712-1723May 1, 2014DOI: 10.1056/NEJMoa1303657
- Abstract
Background
Improved diagnostic tests for tuberculosis in children are needed. We hypothesized that transcriptional signatures of host blood could be used to distinguish tuberculosis from other diseases in African children who either were or were not infected with the human immunodeficiency virus (HIV).
Methods
The study population comprised prospective cohorts of children who were undergoing evaluation for suspected tuberculosis in South Africa (655 children), Malawi (701 children), and Kenya (1599 children). Patients were assigned to groups according to whether the diagnosis was culture-confirmed tuberculosis, culture-negative tuberculosis, diseases other than tuberculosis, or latent tuberculosis infection. Diagnostic signatures distinguishing tuberculosis from other diseases and from latent tuberculosis infection were identified from genomewide analysis of RNA expression in host blood.
Results
We identified a 51-transcript signature distinguishing tuberculosis from other diseases in the South African and Malawian children (the discovery cohort). In the Kenyan children (the validation cohort), a risk score based on the signature for tuberculosis and for diseases other than tuberculosis showed a sensitivity of 82.9% (95% confidence interval [CI], 68.6 to 94.3) and a specificity of 83.6% (95% CI, 74.6 to 92.7) for the diagnosis of culture-confirmed tuberculosis. Among patients with cultures negative for Mycobacterium tuberculosis who were treated for tuberculosis (those with highly probable, probable, or possible cases of tuberculosis), the estimated sensitivity was 62.5 to 82.3%, 42.1 to 80.8%, and 35.3 to 79.6%, respectively, for different estimates of actual tuberculosis in the groups. In comparison, the sensitivity of the Xpert MTB/RIF assay for molecular detection of M. tuberculosis DNA in cases of culture-confirmed tuberculosis was 54.3% (95% CI, 37.1 to 68.6), and the sensitivity in highly probable, probable, or possible cases was an estimated 25.0 to 35.7%, 5.3 to 13.3%, and 0%, respectively; the specificity of the assay was 100%.
Conclusions
RNA expression signatures provided data that helped distinguish tuberculosis from other diseases in African children with and those without HIV infection. (Funded by the European Union Action for Diseases of Poverty Program and others).
Media in This Article
Figure 1
Overall Study Design and Numbers of Children Included in the Discovery and Validation Cohorts.Figure 2
Diagnostic Algorithm.Article Activity
- Article
Between 500,000 and 1 million new cases of childhood tuberculosis are diagnosed annually, but the true global burden of childhood tuberculosis is unknown because it is often difficult to confirm the diagnosis microbiologically.1-3 Although most cases of tuberculosis in adults are diagnosed through detection of acid-fast bacilli on microscopic examination of a sputum specimen, in the majority of childhood cases, smears and cultures are negative for Mycobacterium tuberculosis, and the diagnosis is made solely on clinical grounds.1,3 Since the symptoms and signs of childhood tuberculosis are seen in a range of other conditions, clinical diagnosis is unreliable.4 Clinical scoring systems designed to aid diagnosis have not been validated against the standard of culture-confirmed diagnosis, and the diagnostic accuracy of these systems varies markedly.5-7 Overdiagnosis and thus inappropriate treatment of childhood tuberculosis is common.8 Conversely, underdiagnosis contributes to a poor outcome,9 and tuberculosis is often identified only when patients are critically ill or at postmortem investigations.10
Microbiologic diagnosis of childhood tuberculosis usually requires hospital admission to obtain gastric-lavage fluids or saline-induced sputum.11 Even then, microbiologic confirmation is achieved in only a small proportion of treated cases because of the paucibacillary nature of childhood tuberculosis and the characteristic extrapulmonary presentation.1-3 Radiographic findings in childhood tuberculosis are nonspecific,12 and the tuberculin skin test and interferon-γ–release assay (IGRA) cannot differentiate active disease from latent infection.13 Furthermore, children with tuberculosis, particularly those who are infected with the human immunodeficiency virus (HIV) or are malnourished, may have nonreactive results for both the tuberculin skin test and the IGRA.14-17 Improved methods for diagnosing childhood tuberculosis are thus urgently needed, particularly in countries of sub-Saharan Africa where the burden of tuberculosis and HIV coinfection is highest.1,2,18-20 We investigated the use of genomewide RNA expression in host blood to distinguish tuberculosis from other diseases that are prevalent among African children with and those without HIV infection and explored the use of a score for disease risk derived from the transcriptional signature as the basis for a possible diagnostic test.
Methods
Study Conduct and Oversight
We recruited patients between February 17, 2008, and January 27, 2011. Clinical data were anonymized, and patient samples identified according to study number. Assignments to diagnostic groups were made independently by two experienced clinicians, and any discrepancies in these assignments were resolved by a third clinician. Statistical analysis was conducted after the database on RNA expression and the clinical database had been locked (on February 4, 2011). An analysis plan was approved and analysis commenced after an amendment was made to use the South African and Malawi cohorts for discovery of the RNA signature and the Kenyan cohort for validation. This decision was necessitated by the lower-than-expected recruitment rate for patients with culture-confirmed tuberculosis. All the authors confirm that the analysis plan was followed and accept responsibility for the conduct of the study and the accuracy of the data.
The study was approved by the research ethics committees of the University of Cape Town, South Africa; the University of Malawi, College of Medicine; the Liverpool School of Tropical Medicine; Imperial College London; and the Kenya Medical Research Institute. Trained health workers obtained written or oral informed consent from the patients' parents or guardians in their vernacular language. Neither the authors nor the sponsors have commercial interests in the outcomes. Patent applications for the pediatric RNA signatures have been submitted on behalf of the partner institutions, with the aim of the future development of a test for childhood tuberculosis in Africa on a nonprofit basis.
Study Design
We recruited children from three African countries with a high burden of tuberculosis. To identify RNA-transcript signatures associated with active tuberculosis, we used a discovery cohort comprising children evaluated for suspected tuberculosis in hospitals in South Africa and Malawi. We then assessed the performance of these signatures in an independent validation cohort of children evaluated for suspected tuberculosis in hospitals in Kenya. The overall study design is shown in Figure 1Figure 1
Overall Study Design and Numbers of Children Included in the Discovery and Validation Cohorts.. Further details on the study design and study sites are provided in the protocol and in the Methods section and Fig. S1 in the Supplementary Appendix; the protocol and the Supplementary Appendix are available with the full text of this article at NEJM.org. Gene-expression data are available at the National Center for Biotechnology Information Gene Expression Omnibus (GEO) and can be accessed through GEO Series accession number GSE39941 at www.ncbi.nlm.nih.gov/geo.Diagnostic Process
A systematic diagnostic evaluation was performed in children younger than 15 years of age who had a cough, fever, or weight loss of more than 2 weeks' duration; pneumonia that was unresponsive to antibiotics; any other clinical findings that were suggestive of tuberculosis; or a history of close contact with an adult who had tuberculosis (Figure 2Figure 2
Diagnostic Algorithm.). The investigation included chest radiography, measurement of the C-reactive protein level, a serologic test or polymerase-chain-reaction (PCR) assay for HIV, and a tuberculin skin test, with or without an IGRA. Two spontaneous or induced sputum samples and a specimen of tissue or cerebrospinal fluid (if clinically indicated) were examined for acid-fast bacilli and cultured for mycobacteria. The Xpert MTB/RIF21 real-time PCR assay (a test for M. tuberculosis and resistance to rifampin) was performed on respiratory samples in the Kenyan cohort. Bacterial cultures, histologic examination of tissue-biopsy specimens, and analysis of blood films for the presence of malaria were performed as clinically indicated. Clinical follow-up was undertaken at 3 months to confirm that children with latent tuberculosis infection remained free of active tuberculosis and other diseases and to determine whether there had been a response to treatment in children with confirmed or suspected tuberculosis.Case Definitions
Culture-confirmed tuberculosis was defined as the isolation of M. tuberculosis from a child with clinical features of tuberculosis, and culture-negative tuberculosis was defined as a negative mycobacterial culture in a child with clinical and radiologic features that prompted empirical treatment for tuberculosis. Culture-negative tuberculosis was further categorized as a case in which tuberculosis was highly probable, probable, or possible on the basis of a priori study definitions (Figure 2). Children were classified as having latent tuberculosis infection if they had contact with a person who had a positive smear for tuberculosis, were healthy on presentation and follow-up, and had positive results on both the tuberculin skin test and the IGRA if in the discovery cohort and had positive results on either the tuberculin skin test or the IGRA if in the validation cohort. Children were classified as having diseases other than tuberculosis if they received a definitive alternative diagnosis or had no clinical deterioration on follow-up in the absence of tuberculosis therapy (Figure 2). Since a positive result on an IGRA in the group of patients with diseases other than tuberculosis might indicate either latent tuberculosis infection or primary tuberculosis that had resolved without treatment, we excluded patients in the discovery cohort who had a positive result on an IGRA. In the Kenyan validation cohort, patients who had diseases other than tuberculosis were included in the study regardless of whether an IGRA result was positive or negative.
Microarray Analysis of Blood RNA Expression
Whole blood was collected in PAXgene Blood RNA Tubes (PreAnalytiX) at the time of study recruitment, frozen within 6 hours after collection, and later extracted with the use of PAXgene Blood RNA Kits. RNA was shipped to the Genome Institute of Singapore for analysis on HumanHT-12 v.4 Expression BeadChip arrays (Illumina). Information on microarray methods, quality control, and analysis is provided in the Methods section and Fig. S2 in the Supplementary Appendix.
Statistical Analysis
Gene-expression data were analyzed with the use of R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing). Patients in the discovery cohort were assigned to training and test sets (80% and 20% of the cohort, respectively). We used the training set to identify transcripts that were differentially expressed between tuberculosis and other diseases and also between active tuberculosis and latent infection, irrespective of HIV status or geographic location; differential expression was defined as an absolute log2 intensity ratio of more than 0.5. To identify the smallest number of transcripts distinguishing tuberculosis from the comparator groups, we subjected these transcripts to variable selection using elastic net22 (see the Methods section in the Supplementary Appendix).
Array-based technologies are not appropriate for use in resource-poor regions because of their cost and the complex technology required. We therefore developed a method for translating multitranscript RNA signatures into a single score for disease risk that could form the basis of a simple diagnostic test. Transcripts from the minimal signatures were classified as up-regulated or down-regulated on the basis of their expression relative to each comparator group in the training data set. The risk score for disease was derived by adding the total intensity of the up-regulated transcripts and subtracting the total intensity of the down-regulated transcripts (see Equation 1 in the Methods section in the Supplementary Appendix). For each patient, we calculated the risk score using the minimal transcript sets for tuberculosis as compared with other diseases and as compared with latent tuberculosis infection.
In the Kenyan validation cohort, we compared the performance of the disease risk score with that of Xpert MTB/RIF assay within each of four groups: the group with culture-confirmed tuberculosis and the culture-negative groups with highly probable, probable, or possible tuberculosis. In each evaluation, the same tuberculosis-negative comparator group (i.e., children with diseases other than tuberculosis) was used to calculate test specificity (Table 1Table 1
Clinical Characteristics of Children in the Kenyan Validation Cohort.). We used a range of estimates of the true rate of positive test results for tuberculosis in the groups with highly probable, probable, or possible tuberculosis in order to model the performance of the risk score and the Xpert MTB/RIF assay and to provide an estimate of the sensitivity of each test (effective sensitivity) (see the Methods section in the Supplementary Appendix).Results
Discovery Cohort
After screening and evaluating 1356 children in South Africa and Malawi for symptoms of tuberculosis, we included 157 patients from South Africa and 189 patients from Malawi in the RNA expression studies. Of these 346 children, 114 had culture-confirmed tuberculosis, 175 had diseases other than tuberculosis, and 57 had latent tuberculosis infection. The discovery cohort included only those children with tuberculosis that was confirmed on culture; children for whom the diagnosis of tuberculosis could not be confidently established or ruled out were excluded. (Details of recruitment are provided in Fig. S1A and S1B and clinical details in Table S1A and S1B in the Supplementary Appendix.)
Identification of Tuberculosis Signature
In the training set (comprising 80% of samples from the discovery cohort), we identified 409 transcripts that were differentially expressed between tuberculosis and other diseases and 3434 transcripts that were differentially expressed between tuberculosis and latent infection. Using variable selection to identify the smallest number of transcripts that distinguished each group, we found that 51 transcripts distinguished tuberculosis from other diseases and 42 distinguished tuberculosis from latent infection (Table S2A and S2B in the Supplementary Appendix). These minimal transcript sets were used to generate a risk score for each patient in the test set (comprising the remaining 20% of samples from the discovery cohort) that distinguished tuberculosis from other diseases (sensitivity of 78% and specificity of 74%) and that distinguished tuberculosis from latent infection (sensitivity of 96% and specificity of 91%) (Table 2Table 2
Diagnostic Performance of the Risk Score in the Discovery and Validation Cohorts and as Compared with the IGRA and the Xpert MTB/RIF Assay in the Validation Cohort., and Table S3 and Fig. S3 and S4 in the Supplementary Appendix).Assessment of Risk Score in Validation Cohort
A total of 1599 children presenting to hospitals in Kenya met the inclusion criteria for the study, and 1471 were evaluated for tuberculosis.23 We included 157 of these children in a nested case–control study that included the group with culture-confirmed tuberculosis and all subgroups in the group with culture-negative tuberculosis (i.e., those in whom tuberculosis was highly probable, probable, or possible). We included all patients with culture-confirmed tuberculosis or latent infection for whom we had adequate RNA samples (35 and 14 patients, respectively), 44 patients with culture-negative tuberculosis (8 patients in whom tuberculosis was highly probable, 19 in whom it was probable, and 17 in whom it was possible) (Table S4 in the Supplementary Appendix), and 64 randomly selected patients from the group with diseases other than tuberculosis (55 with negative IGRA results and 9 with positive IGRA results). Clinical features of the patients included in the microarray study, which are summarized in Table 1, were similar to the clinical features of patients who were not included, with two exceptions: in the group with probable tuberculosis, a history of close contact with a person who had tuberculosis was more common among patients included in the microarray study (Table S5A in the Supplementary Appendix), and in the group with diseases other than tuberculosis, weight loss and pleural effusion were more common among patients who were included (Table S5B in the Supplementary Appendix).
The risk score discriminated culture-confirmed tuberculosis from other diseases in patients with or without HIV infection with a sensitivity of 82.9% and a specificity of 83.6% when patients with other diseases who had a positive IGRA result were excluded. When patients in the group with diseases other than tuberculosis who had a positive IGRA result were included, the specificity and sensitivity of the risk score were not affected (Table 2 and Figure 3Figure 3
Risk Scores and Sensitivity and Specificity in the Kenyan Validation Cohort, According to Diagnostic Group., and Table S6 and Fig. S5 in the Supplementary Appendix). The majority of patients in the group with diseases other than tuberculosis who had a positive IGRA result were classified as not having tuberculosis (7 of 9 patients) (see the Methods section and Fig. S3 in the Supplementary Appendix). Among patients with negative cultures who were treated for tuberculosis, the risk score identified 62.5% of those in whom tuberculosis was highly probable, 42.1% of those in whom it was probable, and 35.3% of those in whom it was possible. Since it was not known what proportion of patients had actual tuberculosis (as opposed to patients who were treated on the basis of suspicion of disease), we adjusted for the estimated prevalence of actual tuberculosis in each of these subgroups to calculate an effective sensitivity (see the Methods section in the Supplementary Appendix); the effective sensitivity of the risk score for highly probable, probable, and possible cases of tuberculosis was 67.6 to 82.3%, 59.3 to 80.8%, and 54.3 to 79.6%, respectively (Table S7 in the Supplementary Appendix). The sensitivity of the risk score was higher than that of the Xpert MTB/RIF assay in all tuberculosis categories, with the Xpert MTB/RIF assay having sensitivities of 27.8 to 35.7% for the subgroup in which tuberculosis was highly probable, 8.8 to 13.3% for that in which it was probable, and 0% for that in which it was possible (Figure 3, and Table S7 in the Supplementary Appendix). However, the Xpert MTB/RIF assay was highly specific (100%). The risk score also distinguished tuberculosis from latent infection, with a sensitivity of 94% and a specificity of 100% (Table S3 and Fig. S4 in the Supplementary Appendix). Finally, we compared the diagnostic performance of the risk score with that of the IGRA and measurement of the C-reactive protein level (which has been reported as a biomarker of tuberculosis24). The C-reactive protein level proved to be of no value in discriminating childhood tuberculosis from other diseases (Fig. S6 in the Supplementary Appendix), and for this purpose, the risk score was significantly more sensitive than the IGRA (82.9% vs. 60.0%) (Table 2).To explore the ways in which the risk score might contribute to the diagnosis of tuberculosis in clinical practice, we evaluated its positive and negative predictive value assuming different prevalences of tuberculosis, as follows: 10% (the prevalence in the validation cohort), 30% (the prevalence in the discovery cohort), and 50% (the prevalence that might be expected in a nonresearch setting with greater pretest filtering according to clinical findings). We also included a range of estimates of actual tuberculosis in the study group with culture-negative results (for more information, see the Methods section in the Supplementary Appendix). The negative predictive value was consistently high in all these analyses. As expected, the positive predictive value was higher when more targeted clinical criteria were used to select patients for testing (Table S8 in the Supplementary Appendix).
Discussion
We identified a tuberculosis-specific transcriptome signature in host blood that appears to be valuable in distinguishing tuberculosis from other diseases with similar clinical features in HIV-positive and HIV-negative African children. This prospective study involved the identification of tuberculosis signatures in cohorts from two countries and validation in an independent cohort in a third country. Our findings extend the results of previous studies of transcriptome signatures in adults and children with tuberculosis.25-33
The major challenge in evaluating new biomarkers of childhood tuberculosis is the lack of a reference standard against which to evaluate them,1,2,20 since microbiologic confirmation is achieved in a minority of patients who are treated for tuberculosis. It is generally accepted that clinical diagnostic scores overdiagnose tuberculosis,34 but the extent of overdiagnosis is unknown. Conversely, the diagnosis of tuberculosis is often overlooked in patients who have the disease, and they are often inadvertently treated for other diseases.2 To address this challenge, we first compared the performance of our transcriptome signatures and risk score for disease with the reference standard of culture-confirmed tuberculosis; we then assessed the performance of the signatures in the culture-negative group, for which no reference standard is available. To evaluate biomarkers in patients with culture-negative tuberculosis, we developed an approach in which estimates of the true proportion of patients with tuberculosis in three subgroups (those for whom a diagnosis of tuberculosis was considered highly probable, probable, or possible) were used to calculate an effective sensitivity of the risk score. The gradient in the performance of the risk score in the culture-negative groups was consistent with the different degrees of diagnostic certainty in each group. Our findings suggest that the risk score provides an improved estimate of the actual prevalence of tuberculosis in each diagnostic category and indicate that there is considerable overdiagnosis and overtreatment of childhood tuberculosis, even in research settings where more sophisticated diagnostic tools are available than in most African hospitals.
To define the potential role of our RNA-based approach, we compared our risk score for tuberculosis with other available diagnostic methods, including culture, the Xpert MTB/RIF assay, measurement of the C-reactive protein level, and the IGRA. Although the Xpert MTB/RIF assay is highly specific, our findings confirm the results of other studies35 showing that the sensitivity of this assay for childhood tuberculosis is limited. Our risk score identified higher proportions of culture-confirmed cases of tuberculosis and culture-negative cases than did the Xpert MTB/RIF assay. The risk score was also more sensitive than the IGRA; the C-reactive protein level proved to be a poor biomarker of childhood tuberculosis.
Use of the disease risk score did result in the misclassification of some cases of nontuberculous disease as tuberculosis, which may reflect reduced specificity (perhaps resulting from the wide variation in the other diseases in the study population) or the difficulty of definitively ruling out a diagnosis of tuberculosis among children in populations in which malnutrition, HIV infection, other infections, and primary tuberculosis are common.1 Conversely, some of the patients with culture-negative tuberculosis may in fact have had other diseases that were self-limiting. In areas where there is a high burden of tuberculosis, a considerable proportion of healthy children have latent tuberculosis infection and have positive IGRA results. Since there was no way of establishing whether a child with diseases other than tuberculosis who also had a positive IGRA result had primary tuberculosis or latent infection, we evaluated our risk score with and without the inclusion of children with positive IGRA results. Our finding that the risk score distinguished the majority of children with other diseases from children with tuberculosis, regardless of IGRA positivity, highlights the potential value of the risk score in populations where latent infection is common.
The translation of transcriptional signatures into diagnostic tools in resource-poor communities is challenging. Innovation will be needed to reduce the cost and complexity of the current methods used to detect multiple RNA transcripts.
The best application of a blood test based on our risk score and transcriptional signatures in clinical practice requires further study. The fact that the negative predictive value of the risk score is higher than its positive predictive value suggests that the score may be more useful for ruling out tuberculosis than for confirming the diagnosis. The development of a test based on this risk score for tuberculosis could improve the diagnosis and surveillance of childhood tuberculosis in areas with a high or low burden of disease.
Supported by a grant from the European Union Action for Diseases of Poverty Program (Sante–2006–105-061), a Malawi–Liverpool–Wellcome Trust Clinical Research Program Core Grant, United Kingdom (084679–Z–08–Z, to Dr. Heyderman), and additional grants from the Wellcome Trust (084323 and 088316, to Dr. Wilkinson; 081835, to Dr. Scott; and 081697, to Dr. Brent); the study also made use of infrastructure and staff at the Wellcome Trust–supported programs in Blantyre, Malawi, and Kilifi, Kenya, the University of Cape Town (084323, 077092), the Imperial College Wellcome Trust Centre for Clinical Tropical Medicine, and the Imperial College Wellcome Trust Centre for Global Health Research.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
The authors report that some of the work has been submitted as a patent application by Imperial College Innovations. No other potential conflict of interest relevant to this article was reported.
Dr. Anderson, Ms. Kaforou, Dr. Brent, and Dr. Wright, as well as Drs. Coin, Heyderman, and Levin and Dr. Eley, contributed equally to this article.
We thank the patients who participated in the study and Dr. Hajara Elbusaidy (provincial tuberculosis and leprosy coordinator, Coast Province, Kenya) for her support of the study.
Source Information
The authors' affiliations are listed in the Appendix.
Address reprint requests to Dr. Levin at the Section of Paediatrics and Imperial College–Wellcome Trust Centre for Global Health Research, Department of Medicine, Imperial College London, Norfolk Pl., London W2 1PG, United Kingdom.
A complete list of members of the Imperial College, Liverpool University/Malawi College of Medicine/Wellcome Trust Research Program, University of Sussex, London School of Hygiene, and University of Cape Town (ILULU) Consortium and the Kilifi Improving Diagnosis and Surveillance of Childhood Tuberculosis (KIDS TB) Study Group is provided in the Supplementary Appendix, available at NEJM.org.
Appendix
The authors' affiliations are as follows: Brighton and Sussex Medical School, University of Sussex, Brighton (S.T.A., C.M.B., F.K.), Section of Paediatrics and Wellcome Trust Centre for Clinical Tropical Medicine, Division of Infectious Diseases, Department of Medicine (M.K., A.J.B., V.J.W., M.S.H., P.R.L., R.J.W., M.L.), and the Department of Genomics of Common Disease, School of Public Health (M.K., L.J.C.), Imperial College London, and the Departments of Infectious Disease Epidemiology (A.C.C., N.F.) and Immunology and Infection (H.M.D.), London School of Hygiene and Tropical Medicine, London, Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford (A.J.B.), and the Institute of Infection and Global Health, University of Liverpool (N.F.), and Liverpool School of Tropical Medicine (R.S.H.), Liverpool — all in the United Kingdom; Malawi–Liverpool–Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine (S.T.A., C.M.B., G.C., R.M., R.S.H.), and Department of Pediatrics, Queen Elizabeth Central Hospital (G.C., R.M.), Blantyre, and the Karonga Prevention Study, Chilumba, Karonga District (A.C.C., N.F.) — all in Malawi; Kenya Medical Research Institute–Wellcome Trust Research Programme, Kilifi (A.J.B., J.A.G.S.), and the Department of Paediatrics, Coast Provincial General Hospital, Mombasa (H.T.) — both in Kenya; Infectious Disease, Genome Institute of Singapore, Singapore (M.L.H., L.L.); the Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands (T.H.M.O.); Red Cross War Memorial Children's Hospital (S.P., V.P., B.E.) and Institute of Infectious Disease and Molecular Medicine (R.J.W.), University of Cape Town, Cape Town, South Africa; and the Institute for Molecular Bioscience, University of Queensland, St. Lucia, Australia (L.J.C.).
- References
References
1
Perez-Velez CM Marais BJ
Full Text | Web of Science | Medline2
Global tuberculosis report 2012. Geneva: World Health Organization, 2012.
3
Zar HJ Connell TG Nicol M
CrossRef | Web of Science | Medline4
Marais BJ Gie RP Obihara CC Hesseling AC Schaaf HS Beyers N
CrossRef | Web of Science | Medline5
Hatherill M Hanslo M Hawkridge T
CrossRef | Web of Science | Medline6
Hesseling AC Schaaf HS Gie RP Starke JR Beyers N
Web of Science | Medline7
Pearce EC Woodward JF Nyandiko WM Vreeman RC Ayaya SO
CrossRef8
Cuevas LE Petrucci R Swaminathan S
CrossRef | Web of Science9
Drobac PC Shin SS Huamani P
CrossRef | Web of Science | Medline10
Chintu C Mudenda V Lucas S
CrossRef | Web of Science | Medline11
Zar HJ Hanslo D Apolles P Swingler G Hussey G
CrossRef | Web of Science | Medline12
Swingler GH du Toit G Andronikou S van der Merwe L Zar HJ
CrossRef | Web of Science | Medline13
Machingaidze S Wiysonge CS Gonzalez-Angulo Y
CrossRef | Web of Science | Medline14
Mandalakas AM Detjen AK Hesseling AC Benedetti A Menzies D
CrossRef | Web of Science | Medline15
Eamranond P Jaramillo E
Web of Science | Medline16
Graham SM, Marais BJ, Gie RP. Clinical features and index of suspicion of tuberculosis in children. In: Schaaf HS, Zumla A, eds. Tuberculosis: a comprehensive reference. Philadelphia: Saunders Elsevier, 2009:154-63.
17
Kampmann B Whittaker E Williams A
CrossRef | Web of Science | Medline18
Brent AJ
CrossRef | Medline19
Hatherill M Verver S Mahomed H
CrossRef | Web of Science | Medline20
Whittaker E Zar HJ
CrossRef | Web of Science21
Boehme CC Nabeta P Hillemann D
Free Full Text | Web of Science | Medline22
Zou H Hastie T
CrossRef23
Graham SM Ahmed T Amanullah F
CrossRef | Web of Science | Medline24
Wallis RS Pai M Menzies D
CrossRef | Web of Science | Medline25
Berry MP Graham CM McNab FW
CrossRef | Web of Science | Medline26
Jacobsen M Repsilber D Gutschmidt A
CrossRef | Web of Science | Medline27
Lesho E Forestiero FJ Hirata MH
CrossRef | Web of Science | Medline28
Lu C Wu J Wang H
CrossRef | Web of Science | Medline29
Maertzdorf J Weiner J III Mollenkopf HJ
CrossRef | Web of Science | Medline30
Mistry R Cliff JM Clayton CL
CrossRef | Web of Science | Medline31
Ottenhoff TH Dass RH Yang N
CrossRef | Web of Science | Medline32
Verhagen LM Zomer A Maes M
CrossRef | Web of Science | Medline33
Kaforou M Wright VJ Oni T
CrossRef | Web of Science | Medline34
Cuevas LE Browning R Bossuyt P
CrossRef | Web of Science | Medline35
Nicol MP Workman L Isaacs W
CrossRef | Web of Science | Medline
- Citing Articles (40)
Citing Articles
1
Sylvia M. LaCourse, Lisa M. Cranmer, Daniel Matemo, John Kinuthia, Barbra A. Richardson, Grace John-Stewart, David J. Horne. (2016) Tuberculosis Case Finding in HIV-Infected Pregnant Women in Kenya Reveals Poor Performance of Symptom Screening and Rapid Diagnostic Tests. JAIDS Journal of Acquired Immune Deficiency Syndromes 71, 219-227
CrossRef2
Tom A Yates, Palwasha Y Khan, Gwenan M Knight, Jonathon G Taylor, Timothy D McHugh, Marc Lipman, Richard G White, Ted Cohen, Frank G Cobelens, Robin Wood, David A J Moore, Ibrahim Abubakar. (2016) The transmission of Mycobacterium tuberculosis in high burden settings. The Lancet Infectious Diseases 16, 227-238
CrossRef3
E. L. Tsalik, R. Henao, M. Nichols, T. Burke, E. R. Ko, M. T. McClain, L. L. Hudson, A. Mazur, D. H. Freeman, T. Veldman, R. J. Langley, E. B. Quackenbush, S. W. Glickman, C. B. Cairns, A. K. Jaehne, E. P. Rivers, R. M. Otero, A. K. Zaas, S. F. Kingsmore, J. Lucas, V. G. Fowler, L. Carin, G. S. Ginsburg, C. W. Woods. (2016) Host gene expression classifiers diagnose acute respiratory illness etiology. Science Translational Medicine 8, 322ra11-322ra11
CrossRef4
Synne Jenum, S. Dhanasekaran, Rakesh Lodha, Aparna Mukherjee, Deepak Kumar Saini, Sarman Singh, Varinder Singh, Guruprasad Medigeshi, Marielle C. Haks, Tom H. M. Ottenhoff, Timothy Mark Doherty, Sushil K. Kabra, Christian Ritz, Harleen M. S. Grewal. (2016) Approaching a diagnostic point-of-care test for pediatric tuberculosis through evaluation of immune biomarkers across the clinical disease spectrum. Scientific Reports 6, 18520
CrossRef5
James T. Rosenbaum, Cailin H. Sibley, Dongseok Choi, Christina A. Harrington, Stephen R. Planck. (2016) Molecular diagnosis: Implications for ophthalmology. Progress in Retinal and Eye Research 50, 25-33
CrossRef6
J. L. Gardiner, C. L. Karp. (2015) Transformative tools for tackling tuberculosis. Journal of Experimental Medicine 212, 1759-1769
CrossRef7
Mark Patrick Nicol, Devasena Gnanashanmugam, Renee Browning, Eleanor S. Click, Luis E. Cuevas, Anne Detjen, Steve M. Graham, Michael Levin, Mamodikoe Makhene, Payam Nahid, Carlos M. Perez-Velez, Klaus Reither, Rinn Song, Hans M. L. Spiegel, Carol Worrell, Heather J. Zar, Gerhard Walzl. (2015) A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis: Table 1.. Clinical Infectious Diseases 61, S164-S172
CrossRef8
Paul Elkington, Alimuddin Zumla. (2015) Update in Mycobacterium tuberculosis Lung Disease 2014. American Journal of Respiratory and Critical Care Medicine 192, 793-798
CrossRef9
Keertan Dheda, Clifton E Barry, Gary Maartens. (2015) Tuberculosis. The Lancet
CrossRef10
Marc Tebruegge, Nicole Ritz, Nigel Curtis, Delane Shingadia. (2015) Diagnostic Tests for Childhood Tuberculosis. The Pediatric Infectious Disease Journal 34, 1014-1019
CrossRef11
Ulrich von Both, Myrsini Kaforou, Michael Levin, Sandra M. Newton. (2015) Understanding immune protection against tuberculosis using RNA expression profiling. Vaccine 33, 5289-5293
CrossRef12
Jacqueline M. Achkar, Laetitia Cortes, Pascal Croteau, Corey Yanofsky, Marija Mentinova, Isabelle Rajotte, Michael Schirm, Yiyong Zhou, Ana Paula Junqueira-Kipnis, Victoria O. Kasprowicz, Michelle Larsen, René Allard, Joanna Hunter, Eustache Paramithiotis. (2015) Host Protein Biomarkers Identify Active Tuberculosis in HIV Uninfected and Co-infected Individuals. EBioMedicine 2, 1160-1168
CrossRef13
Silvia S. Chiang, Douglas S. Swanson, Jeffrey R. Starke. (2015) New Diagnostics for Childhood Tuberculosis. Infectious Disease Clinics of North America 29, 477-502
CrossRef14
Diala Faddoul. (2015) Childhood Tuberculosis. Advances in Pediatrics 62, 59-90
CrossRef15
Alan Dove. (2015) To build better tuberculosis diagnostics, look for 'biosignatures'. Nature Medicine 21, 662-662
CrossRef16
L D Tientcheu, J Maertzdorf, J Weiner, I M Adetifa, H-J Mollenkopf, J S Sutherland, S Donkor, B Kampmann, S H E Kaufmann, H M Dockrell, M O Ota. (2015) Differential transcriptomic and metabolic profiles of M. africanum- and M. tuberculosis-infected patients after, but not before, drug treatment. Genes and Immunity 16, 347-355
CrossRef17
Elisabetta Venturini, Giulia Remaschi, Elettra Berti, Carlotta Montagnani, Luisa Galli, Maurizio de Martino, Elena Chiappini. (2015) What steps do we need to take to improve diagnosis of tuberculosis in children?. Expert Review of Anti-infective Therapy 13, 907-922
CrossRef18
N Satproedprai, N Wichukchinda, S Suphankong, W Inunchot, T Kuntima, S Kumpeerasart, S Wattanapokayakit, S Nedsuwan, H Yanai, K Higuchi, N Harada, S Mahasirimongkol. (2015) Diagnostic value of blood gene expression signatures in active tuberculosis in Thais: a pilot study. Genes and Immunity 16, 253-260
CrossRef19
(2015) Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014. Vaccine 33, 3047-3055
CrossRef20
Grant Theron. (2015) Xpert MTB/RIF to diagnose tuberculosis in children. The Lancet Respiratory Medicine 3, 419-421
CrossRef21
O. M. P. Jolobe. (2015) A promising test to distinguish between active tuberculosis and latent tuberculosis. QJM 108, 515-515
CrossRef22
Ilana C van Rensburg, André G Loxton. (2015) Transcriptomics: the key to biomarker discovery during tuberculosis?. Biomarkers in Medicine 9, 483-495
CrossRef23
David Wendler. (2015) "Targeted" Consent for Pragmatic Clinical Trials. Journal of General Internal Medicine 30, 679-682
CrossRef24
M. Pai, M. Schito. (2015) Tuberculosis Diagnostics in 2015: Landscape, Priorities, Needs, and Prospects. Journal of Infectious Diseases 211, S21-S28
CrossRef25
Ruth McNerney, Jane Cunningham, Pamela Hepple, Alimuddin Zumla. (2015) New tuberculosis diagnostics and rollout. International Journal of Infectious Diseases 32, 81-86
CrossRef26
Katharina Ronacher, Simone A. Joosten, Reinout van Crevel, Hazel M. Dockrell, Gerhard Walzl, Tom H. M. Ottenhoff. (2015) Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. Immunological Reviews 264:10.1111/imr.2015.264.issue-1, 121-137
CrossRef27
Delphi Chatterjee, Arun K. Pramanik. (2015) Tuberculosis in the African continent: A comprehensive review. Pathophysiology 22, 73-83
CrossRef28
Luke D. Jasenosky, Thomas J. Scriba, Willem A. Hanekom, Anne E. Goldfeld. (2015) T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunological Reviews 264:10.1111/imr.2015.264.issue-1, 74-87
CrossRef29
Jacqueline M. Cliff, Stefan H. E. Kaufmann, Helen McShane, Paul van Helden, Anne O'Garra. (2015) The human immune response to tuberculosis and its treatment: a view from the blood. Immunological Reviews 264:10.1111/imr.2015.264.issue-1, 88-102
CrossRef30
Jacquie N Oliwa, Jamlick M Karumbi, Ben J Marais, Shabir A Madhi, Stephen M Graham. (2015) Tuberculosis as a cause or comorbidity of childhood pneumonia in tuberculosis-endemic areas: a systematic review. The Lancet Respiratory Medicine 3, 235-243
CrossRef31
Damien Chaussabel. (2015) Assessment of immune status using blood transcriptomics and potential implications for global health. Seminars in Immunology 27, 58-66
CrossRef32
Andrea Rachow, Norbert Heinrich, Christof Geldmacher. (2015) Early Identification of Progressive TB Disease Using Host Biomarkers. EBioMedicine 2, 107-108
CrossRef33
Atana Uket Ewa, Dominic Fabian Essiet, Samuel John Umejei Monu. (2015) Tuberculosis in Children Living amongst Adults with Tuberculosis at the Tuberculosis and Leprosy Referral Hospital, Eku, Nigeria. Journal of Tuberculosis Research 03, 80-89
CrossRef34
Sung-Han Kim. (2014) Diagnosis and Treatment of Tuberculous Meningitis. Journal of Neurocritical Care 7, 78-85
CrossRef35
Amy Y. Vittor, Joseph M. Garland, Robert H. Gilman. (2014) Molecular Diagnosis of TB in the HIV Positive Population. Annals of Global Health 80, 476-485
CrossRef36
Myrsini Kaforou, Victoria J. Wright, Michael Levin. (2014) Host RNA signatures for diagnostics: An example from paediatric tuberculosis in Africa. Journal of Infection 69, S28-S31
CrossRef37
Digby F Warner, Valerie Mizrahi. (2014) Translating genomics research into control of tuberculosis: lessons learned and future prospects. Genome Biology 15
CrossRef38
Annelies Van Rie, Harry Moultrie. (2014) Novel biomarkers for paediatric tuberculosis. The Lancet Infectious Diseases 14, 900-901
CrossRef39
Aimee K. Zaas, Bronwen H. Garner, Ephraim L. Tsalik, Thomas Burke, Christopher W. Woods, Geoffrey S. Ginsburg. (2014) The current epidemiology and clinical decisions surrounding acute respiratory infections. Trends in Molecular Medicine 20, 579-588
CrossRef40
David Gurwitz. (2014) From Transcriptomics to Biological Networks. Drug Development Research 75:10.1002/ddr.2014.75.issue-5, 267-270
CrossRef
